Cholinergic basal forebrain degeneration is associated with central fatigue in Parkinson's disease
Li Li1, Xiaodan Zhang1,2, Mateng Wang3
1Department of Neurology, Ningbo No.2 Hospital, Ningbo, China.
Background:
Central fatigue is a prevalent and debilitating non-motor symptom in Parkinson's disease (PD), yet its neurobiological basis remains poorly understood. While cholinergic basal forebrain (CBFB) degeneration has been implicated in various PD symptoms, its specific relationship with central fatigue has not been systematically investigated using neuroimaging.
Methods:
In this cross-sectional study, 49 patients with PD underwent 3.0 T brain structural magnetic resonance imaging (MRI) and completed the Fatigue Severity Scale (FSS). Gray matter density (GMD) and gray matter volume (GMV) of CBFB subregions [cholinergic nucleus 4 (Ch4) and cholinergic nucleus 123 (Ch123)] were quantified using voxel-based morphometry with validated probabilistic atlases. Multiple linear regression models examined associations between FSS scores and regional GMD/GMV, adjusting for age, sex, and total intracranial volume (TIV).
Results:
Fatigue severity showed significant negative correlations with bilateral Ch4 integrity across both morphometric measures. Specifically, higher FSS scores were associated with reduced GMD in total, left, and right Ch4, and with smaller GMV in total and right Ch4. A weaker but significant negative correlation was also observed between fatigue and left Ch123 GMD, whereas no association was found with Ch123 GMV. Crucially, parallel analyses of GMD and GMV yielded convergent results, reinforcing the robustness of the Ch4-fatigue relationship.
Conclusion:
This study provides initial neuroimaging evidence linking cholinergic basal forebrain structural integrity with central fatigue in Parkinson's disease. The consistent associations observed between fatigue severity and bilateral Ch4 morphology, supported by parallel GMD and GMV analyses, suggest a potential role for CBFB degeneration in PD-related fatigue. While further validation is needed, these findings contribute to the growing evidence supporting cholinergic involvement in non-motor symptoms and highlight Ch4 as a promising region for future investigations into fatigue mechanisms.
More Related Videos
08:33Targeting Alpha Synuclein Aggregates in Cutaneous Peripheral Nerve Fibers by Free-floating Immunofluorescence Assay
Published on: June 25, 2019
06:07Author Spotlight: Establishing a New Fluorescence-Based Protocol for In Vivo Mitochondrial Morphology Analysis in Parkinson's Disease
Published on: June 23, 2023
Related Concept Videos
01:15Parkinson's Disease: Overview
01:24Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
01:37Neural Regulation
01:30Indirect-Acting Cholinergic Agonists: Pharmacological Actions
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
01:26Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
01:18Indirect-Acting Cholinergic Agonists: Mechanism of Action
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...